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In the last decade, there have been remarkable advances in the medical management of patients with idiopathic pulmonary arterial hypertension (IPAH). These therapies have improved the quality of life, saved many lives and in some cases obviated the need for lung transplantation.
However, the reality is that the majority of patients with IPAH, even with access to the best medical therapy, continue to progress and will require lifesaving lung transplantation.
Lung transplantation for PAH has traditionally been viewed as a higher up front surgical risk lung transplant to perform, but with excellent long term survival and quality of life. The concern in the current management strategy for patients with PAH is, that by virtue of the seriousness of the condition, they tend to have the highest mortality on the lung transplant wait list and then, with the practice of listing them after they begin to fail first, second and sometimes third line medical therapies, they are in even poorer medical condition and generally deteriorating very rapidly. With a limited supply of donor organs, once can see that this might exacerbate the problem of wait list mortality in this particular patient population that cannot afford to wait. One can also appreciate then, that when the UNOS Lung Allocation Score (LAS) was initially introduced, this caused some concern regarding the potential for disadvantaging IPAH patients on the list. The LAS score was designed with the intent to optimize utilization of the scarce resource -donor lungs -by allocation of lungs to patients who have the best potential for a good outcome after transplantation, balancing mortality on the waitlist with survival probability after transplant To optimally treat patients with IPAH, the treating physicians in the IPAH and lung transplant community need to: i) optimize medical care, ii) optimize timing of listing for transplant, and iii) optimize management on the lung transplant waitlist to maximize the likelihood of successful lifesaving lung transplantation in the context of available donor organs ist and then, with the practice of listing them after they begin to fail first, second nd d and nd n s som m omet et etim im imes f hird line medical therapies, they are in even poorer medical condition and generally de ete te eri ri rior or orat at atin in ing g v very ry ry r ra apidly. With a limited supply y y of of f donor organs, s, , onc ce e e c ca can see that this might n ex xac c acerbate the e p pro ro r bl blem em m o o of f f wa wa wait it it l lis is st t t mo mo mort rta ality y y i in n th his s par ar rti ti icu cula lar r r pa pa ati tien ent p p pop pu pula la ati ti ion on t t tha ha hat t c ca ann nn nnot ot t af ffo fo ford rd d t t to o wa wa wait it it. . O On ne e e ca can n al al a s so a a app pp ppre re reci ci ciat ate e e th th he e en n, n, tha ha hat t wh wh when n n t t the he he U UNO NO NOS Lu Lu Lun ng ng A A All ll loc oc o at at a io io on n n Sc Sco or ore e e (L (L LA AS S) ) was initially y in in ntr tr trod od duc uc u ed ed ed, , , th h his is i c c cau au use se s d d d so so ome me me c c con on once ce c rn rn rn r reg eg egar ar rdi di ding ng ng t t the he he p pot ot oten en enti ti tial al al f f for or o d d dis is isad ad adva va vant n aging 3 and current listing guidelines and practices. 
ii) Optimize timing of listing for transplant:
Initially, after the introduction of effective medical therapy for PAH, many patients were taken off lung transplant wait lists (appropriately so) as their condition improved significantly. Many patients were never considered for transplant as they were effectively treated medically from the time of diagnosis. The honeymoon ended at it became evident that many patients would become refractory to medical therapy and begin to deteriorate much more rapidly such that they often could not make it to transplant. The effect of the prostaglandin analogues on platelet function, in combination with warfarin anticoagulation made these patients even higher risk surgical candidates as these lung transplants are done on cardiopulmonary bypass and the ensuing coagulopathy lead to significant issues with perioperative hemorrhage and primary graft dysfunction. Recognizing these issues lead to changes in anticoagulation management practice which has decreased the bleeding risks.
Furthermore, it has become general practice in experienced centers to have PAH patients assessed for possible lung transplantation early on in their disease course so that they can be i) Optimize timing of listing for transplant: Initially, after the introduction of effective me medi di dica ca cal l l th th ther er e a a apy y fo fo for r PAH, many patients were ta a ak k ken n n off lung trans ns spl p an nt t t w w wait lists (appropriately o o) as a their con ondi di d ti i ion n i im m mpr pr prov ov oved ed ed s sig ig gn ni nifi fica ca antly y y. M Many ny ny pa at ati ie ent nt ts s w we wer r re m m m n nev eve e er c con on nsi si side dere re ed d fo fo for r r tr r ra an ans sp spl l lant as s t t the he hey y y we were re re e eff ffe e ect ti tive vely ly t tre reat at ted ed ed m m med ed edic ica a ally ly ly f f fr r rom m m t th h he t tim m me e of of of d dia ia iagn gn nos os sis is is. . Th Th The e ho ho hone ne neym ym ymo o oon n n en n nde ded d d a at at i m m became evide dent nt nt t tha ha hat t t ma ma many ny n p p pat at atie e ent nt nts s wo w w ul ul uld d d be be beco co come me me re re refr frac ac cto to tory ry ry t in the medium to large volume centers described in this paper indeed likely reflects increased experience and access to escalating therapies in the larger centers. In previous years, when PAH patients began to deteriorate they were urgently listed for transplant and had to wait their turn based on time accrued on the waitlist. The pre-LAS system did not take severity of illness into account, hence patients with IPAH that were rapidly deteriorating had few options and had an excessive wait list mortality.
Patients with IPAH tend to die of progressive right heart failure or sudden cardiac death from secondary related arrhythmias when the heart just cannot pump any more against the high resistance of the diseased pulmonary vascular bed. An historical option used to palliate patients was the use of an atrial septostomy. Creating an atrial septostomy would decompress the pressure on the right heart for a period of time, but eventually led to death from biventricular failure secondary to hypoxic perfusion (right to left shunting) of the coronary circulation of the already failing heart. Another option that was sometimes used was extracorporeal lung support (ECLS) instituted in a veno-arterial perfusion conformation -usually femoral vein to femoral artery. This has the benefit of supporting the circulation of the severely decompensated patient, experience and access to escalating therapies in the larger centers. In previous ye ea ars s s, wh wh when en en P P PA A AH patients began to deteriorate they were urgently listed for transplant and had to wait their turn ba ase se ed d d o on on t t tim im ime e e ac c ccr cr cru ued on the waitlist. The pre-L L LAS AS AS system did no no ot t ta ake ke ke s s severity of illness into ac cco o oun u t, hence e p p pat t tie ent nt ts wi wi with th th I IP PA PAH H H th th t a a at w were e e r r rapid dl dly y de de et te teri rio or orat ati ing n ng h had ad d fe ew w o o opt p ptio ions ns ns a a and nd nd h h had ad ad a a an n n ex xce ce cess ss ssiv iv i e e wa wa wait it l li is st t mo mort rta al alit ity.
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http://circ.ahajournals.org/ Downloaded from 5 but often is not successful in that it does not effectively address the right heart failure and the very high pulmonary vascular resistance faced by the heart of a patient with end stage PAH.
We described the use of extracorporeal lung support in a unique fashion for PAH patients 1 . We placed the Novalung R (Novalung, Germany) membrane in parallel to the pulmonary circulation, canulating the pulmonary artery and the left atrium (right superior vein or left atrial appendage) to effectively create a PA-LA shunt. The right ventricle provides the pumping action and hence this membrane is used in a pumpless fashion to effectively create a shunt which also oxygenates the blood while offloading the RV by providing a low resistance (6 mmHg at 1.5L/min flow across the membrane) path for ejection of blood from the right heart.
Since the introduction of this technology, we have decreased the lung transplant wait list mortality for IPAH patients in the Toronto Lung Transplant Program from 22% to 0%
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. ECLS bridging to lung transplantation is an effective therapeutic option that will likely play an increasing role in successfully managing patients on the lung transplant list, to decrease not only wait list mortality, but also post lung transplant survival. These patients can be extubated and ambulatory on ECLS and as such with successful PA-LA bridging come to surgery in far better condition with a recovered right ventricle and recovery of hepatic and renal congestion/failure 2 .
Mallidi and colleagues have studied in a competing outcomes analysis, the cumulative incidence of lung transplant and mortality for waitlisted patients in the period preceding and post the introduction of the UNOS Lung Allocation Score (LAS). 3 The authors have duly acknowledged the limitations of inferences made from the study of registry data. The most important bottom line is that in this analysis, the LAS system does not appear to have specifically disadvantaged patients with IPAH. In fact, to the contrary, this analysis reports that despite of the fact that IPAH patients in the post -LAS era had worse comorbidities (reflected in Since the introduction of this technology, we have decreased the lung transplant t w w wai ai a t t li li list st st mortality for IPAH patients in the Toronto Lung Transplant Program from 22% to 0% 2 . ECLS br rid id dgi gi gin ng ng t t to o o lu lu lung g t t tra ra ran nsplantation is an effective th h her e e a a apeutic option n t t that t wi wi wil ll likely play an n ncr r rea e sing role e in in in s s suc ucc c ces ss ssf fu full ll ly y y ma ma ana na nagi ging ng g pat t tie e ents o on n th h he e lu lung ng ng t tra ra ans s spl plan an nt l l list st, , to to o d dec ec ecre re eas ase n no not t on n nly wa wa ait it i l l lis is ist t mo mo ort rt rtal alit ity, y, b but ut t a als lso o po po ost st t lu lu lung n ng t tr ra rans ns nspl pl plan n nt t t su su urv rv viv v val al. . Th Th Thes es se e e p pa pati ti tien en e t t ts c c can an n b be e e ex ex xtu tu tuba bat t ted d d an an nd d ambulatory o on n n EC EC ECLS LS LS a a and n n a a as s s su s s ch ch ch w w wit it i h h su su succ cc cces es essf sf sful ul l PA PA PA-L -L LA A A br br brid id idgi gi ging ng n c c com om ome e e to to to s sur ur urge ge gery ry ry i i in n n far better 6 higher LAS scores), at two years the incidence of lung transplant as a competing outcome was higher (39% vs. 18%), the incidence of death on the waitlist was lower (23% vs. 31%), and furthermore the post-transplant survival was improved (80% vs. 65% at two years). All encouraging statistics supporting the contention that the LAS is functioning as intended to prioritize sicker patients for transplant and get these patients to transplant sooner. While LTx incidence doubled but post-LTx survival did not increase likely reflects that the patients are still very sick, or sicker, when they get to transplant.
This registry analysis however is not able to account for significant changes in practice that have occurred over the same time period. Importantly, the UNOS registry data does not collect data related to ECLS bridging to lung transplant. The finding that IPAH patients on the waitlist fare better in medium to large centers potentially alludes to this. Specialized centers with increased experience likely have knowledge of and access to progressive IPAH medical therapies and ECLS technologies for bridging patients. The LAS scoring system was intended to be a modifiable scoring system based on analysis of real data over time. Clearly this analysis and adjustment needs to be done to increase the fidelity of the scoring system. The authors have raised provocative questions regarding the role of cardiac index and donor -recipient gender matching that need to be evaluated in more detail. We will also need to look at how to allocate LAS points to patients on a ventilator vs. on extracorporeal lung support.
Conclusions
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